Mobile

Study designed to evaluate the safety and efficacy of AMG 145, in people with elevated LDL-C and not treated with any other lipid-lowering medications.To do this, AMG 145 will be compared with placebo...

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-001362-15

Study designed to evaluate the safety and efficacy of AMG 145, in people with elevated LDL-C and not treated with any other lipid-lowering medications.To do this, AMG 145 will be compared with placebo and with ezetimibe

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Primary objective: To evaluate the effect of 12 weeks of subcutaneous (SC) AMG 145 monotherapy every 2 weeks (Q2W) and monthly (QM), compared with placebo and ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in subjects with a 10-year Framingham risk score of 10% or less.

Critère d'inclusion

  • Dyslipidemia

Liens